Quantcast
Last updated on April 20, 2014 at 7:47 EDT

Latest Biosimilar Stories

2013-10-29 23:22:36

Reportbuyer.com just published a new market research report: World Biological Drugs Market 2013-2023. London (PRWEB) October 29, 2013 Report Details Biologics - discover and assess products with highest revenue potential Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects. In that...

2013-10-29 23:21:37

Reportbuyer.com just published a new market research report: Drug Delivery Technologies: Commercial Prospects 2013-2023. London (PRWEB) October 29, 2013 Report Details Drug delivery technology - discover technological and commercial prospects What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Many commercial opportunities for improved drug delivery exist. You discover sales...

2013-10-28 08:29:30

NEWARK, Del., Oct. 28, 2013 /PRNewswire/ -- iBio, Inc. ( NYSE MKT: IBIO ) today announced receipt on October 25, 2013 of notice from NYSE Regulation that iBio had resolved all previously cited continued listing deficiency with respect to listing standards of the NYSE MKT LLC's (the "Exchange") Company Guide, and therefore continues its listing eligibility, subject, as is the case for all listed issuers, to assessment on an ongoing basis by the Exchange. (Logo:...

2013-10-28 08:28:43

Company To Pursue Next Stage of Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., Oct. 28, 2013 /PRNewswire/ -- Coherus Biosciences, Inc. today announced that its proposed etanercept biosimilar molecule, CHS-0214, an investigational drug, met the primary endpoint of clinical pharmacokinetic (PK) similarity to Enbrel(®) in a confirmatory clinical study in healthy subjects meeting US, EU, and Japanese regulatory requirements for clinical PK...

2013-10-28 08:25:51

Budgets are Limiting Wider Prescribing of Biologics; However, Access Will Improve with the Launch of New Drugs and Biosimilars, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) armamentarium in Argentina and Mexico includes a wide range of premium-priced biologics. However,...

2013-10-22 23:04:59

Reportbuyer.com just published a new market research report: Charting the Biosimilar and Biobetter Development Pipeline (2013). London (PRWEB) October 22, 2013 If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical. The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin,...

2013-10-22 12:28:24

-- Proper naming of biosimilars key for patient access, safety -- LAKE FOREST, Ill., Oct. 22, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, said at the World Health Organization (WHO) today that biosimilar drugs should be given the same nonproprietary names as original biologics to ensure patient access and safe prescribing. Sumant Ramachandra, M.D., Ph.D., senior vice president and chief scientific officer,...

2013-10-17 16:25:03

SAN ANTONIO, Oct. 17, 2013 /PRNewswire-USNewswire/ -- The Academy of Managed Care Pharmacy (AMCP) today established a Biosimilars Task Force to begin developing a Biosimilars Collective Intelligence System to document their safety and efficacy, using continuous analysis of available data for innovator specialty drugs as reference points. Armada Health Care and the Specialty Pharmacy Association of America (SPAARx) are the lead sponsors of the task force and the proposed multi-year...

2013-10-16 23:19:46

It’s not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to Kalorama Information a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it’s in almost everyone’s interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. New York, NY (PRWEB) October 16, 2013 It’s not the first...

2013-10-16 08:27:44

Clinical Results Are Most Influential for Endocrinologists Choosing Between Biosimilars of the Same Reference Brand, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European endocrinologists require extensive efficacy data from multiple Phase III trials, involving in excess of 1,000...